Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib.
Osman ÖcalKerstin SchütteChristoph J ZechChristian LoeweOtto van DeldenVincent VandecaveyeChris VerslypeBernhard GebauerChristian SengelIrene BargelliniRoberto IezziAlexander PhilippThomas BergHeinz J KlümpenJulia BenckertMaciej PechAntonio GasbarriniHolger AmthauerPeter BartensteinBruno SangroPeter MalfertheinerJens RickeMax SeidenstickerPublished in: European journal of nuclear medicine and molecular imaging (2022)
In advanced HCC patients receiving sorafenib, combination with RE has an additive anticancer effect on sorafenib treatment resulting in a higher and longer tumor response. However, the enhanced response did not translate into prolonged survival. Better patient selection and superselective treatment could improve outcomes after combination therapy.